Robert Rosenheck, MD
Professor of Psychiatry, Epidemiology and Public Health, and the Child Study Center, Yale Medical School
Dr Rosenheck has disclosed he received research support from Pfizer Pharmaceuticals to analyze CATIE data and has served as a consultant to Otsuka Pharmaceuticals on a long acting injectable antipsychotic. Dr. Balt has reviewed this article and found no evidence of bias in this educational activity.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
